Article Contents ::
- 1 The Brand Name ORTAN Has Generic Salt :: OLMESARTAN
- 2 ORTAN Is From Company CDC Priced :: Rs. 105
- 3 ORTAN have OLMESARTAN is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ORTAN Has Generic Salt :: OLMESARTAN
ORTAN Is From Company CDC Priced :: Rs. 105
ORTAN have OLMESARTAN is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Hypertension, Diabetic nephropathy,
Drug Dose ::
Oral Hypertension Adult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed. Child: 6-16 yr <35 kg: 10 mg once daily; >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk. Elderly: No dosage adjustment needed. Hepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.
Pregnancy (2nd and 3rd trimesters); biliary obstruction.
Drug Precautions ::
Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Drug Side Effects ::
Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis. Potentially Fatal: Acute renal failure.
Pregnancy category ::
Drug Mode of Action ::
Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
Drug Interactions ::
Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.